Fluorescein isothiocyanate hapten (FITC) (FITC)

Fluorescein isothiocyanate (FITC) is a synthetic small molecule fluorophore that serves as a potent hapten in advanced immunotherapy applications (PubChem CID 18730). When conjugated to an amphiphilic tail, such as a lipid or diacyl group (amph-FITC), the molecule can bind to endogenous albumin and subsequently insert into the lipid bilayer of cell membranes (Ma et al., 2016). This presentation allows the FITC moiety to function as a universal synthetic target for chimeric antigen receptor (CAR) T-cells or bispecific antibodies specifically engineered to recognize the fluorescein molecule (Tamada et al., 2012). This strategy is designed to overcome limitations of traditional CAR-T therapies, such as antigen escape and the lack of suitable endogenous targets, by providing a controllable and programmable bridge between effector immune cells and target cells (Lohmueller et al., 2017). In this context, the FITC hapten does not possess intrinsic biological signaling activity but acts as an anchor for immune-mediated cytotoxicity. The use of amph-FITC allows for "cell painting," where tumor cells or lymph node cells are labeled with the hapten to direct an immune response. This approach is currently being explored in preclinical research to enhance the versatility and safety of adoptive cell transfers by allowing clinicians to potentially modulate the intensity of the T-cell response through adapter dosing.

Other names

FITCFluoresceinamph-FITCMembrane-anchored FITCFluorescein-5-isothiocyanateFITC-hapten

The FITC hapten acts as a synthetic bridge; anti-FITC CAR-T cells or bispecific antibodies bind to the membrane-presented FITC, triggering T-cell activation and targeted lysis of the labeled cell.